LXRX
Lexicon Pharmaceuticals, Inc.
$2.16
-0.07
(-3.14%)
Mkt Cap
959.46M
Volume
1,620,987
52W Range
0.62-2.53
Sector
Healthcare
Beta
0.97
EPS (TTM)
-0.07
P/E Ratio
-8.29
Revenue (TTM)
69.64M
Rev Growth (5Y)
+15.7%
EPS Growth (5Y)
N/A
Company Description
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 49.80M | 31.08M | 1.20M | 139,000 | 298,000 | 24.00M | 322.07M | 63.21M | 90.33M | 83.34M | 130.01M | 22.85M |
| Net Income | (50.34M) | (200.40M) | (177.12M) | (101.94M) | (87.76M) | (58.57M) | 130.13M | (120.55M) | (129.05M) | (141.43M) | (4.68M) | (100.29M) |
| EPS | -0.14 | -0.63 | -0.80 | -0.62 | -0.61 | -0.63 | 1.23 | -1.14 | -1.23 | -1.36 | -0.05 | -1.31 |
| Free Cash Flow | (67.85M) | (179.81M) | (162.37M) | (90.18M) | (88.24M) | (143.06M) | 113.74M | (148.70M) | (185.62M) | (175.86M) | N/A | N/A |
| FCF / Share | -0.19 | -0.56 | -0.73 | -0.54 | -0.61 | -1.29 | 1.07 | -1.41 | -1.77 | -1.69 | N/A | N/A |
| Operating CF | (67.85M) | (178.78M) | (161.90M) | (88.85M) | (87.02M) | (142.97M) | 113.81M | (148.61M) | (185.39M) | (175.63M) | N/A | N/A |
| Total Assets | 184.99M | 298.42M | 229.43M | 194.30M | 136.91M | 203.79M | 417.71M | 284.14M | 436.54M | 475.62M | N/A | N/A |
| Total Debt | 62.24M | 108.40M | 106.06M | 55.29M | 2.28M | 12.81M | 246.84M | 245.00M | 245.67M | 101.45M | N/A | N/A |
| Cash & Equiv | 34.33M | 66.66M | 22.46M | 46.34M | 64.06M | 126.26M | 36.11M | 160.05M | 310.79M | 346.50M | N/A | N/A |
| Book Value | 107.54M | 145.95M | 93.11M | 117.12M | 113.59M | 156.37M | 117.10M | (1.47B) | 52.10M | 157.40M | N/A | N/A |
| Return on Equity | -0.47 | -1.37 | -1.90 | -0.87 | -0.77 | -0.37 | 1.11 | N/A | -2.48 | -0.90 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21.10M | 5.49M | 14.18M | 28.87M | 1.26M | 26.55M | 1.75M | 1.65M | 1.13M | 702,000 | 162,000 | 317,000 |
| Net Income | (1.04M) | (15.53M) | (12.77M) | 3.25M | (25.30M) | (33.77M) | (64.81M) | (53.43M) | (48.40M) | (49.76M) | (50.52M) | (44.90M) |
| EPS | -0.00 | -0.04 | -0.04 | 0.01 | -0.07 | -0.09 | -0.18 | -0.17 | -0.20 | -0.20 | -0.21 | -0.22 |
| Free Cash Flow | (14.73M) | (17.23M) | (23.83M) | 16.99M | (43.78M) | (21.96M) | (53.93M) | (48.79M) | (55.13M) | (50.55M) | (41.70M) | (38.26M) |
| FCF / Share | -0.04 | -0.05 | -0.07 | 0.05 | -0.12 | -0.06 | -0.15 | -0.16 | -0.22 | -0.21 | -0.17 | -0.19 |
| Operating CF | (14.73M) | (17.23M) | (23.83M) | 16.99M | (43.78M) | (21.49M) | (53.62M) | (48.54M) | (55.13M) | (50.55M) | (41.62M) | (38.12M) |
| Total Assets | 268.82M | 184.99M | 205.93M | 225.58M | 297.67M | 298.42M | 321.12M | 373.36M | 417.22M | 229.43M | 276.48M | 316.72M |
| Total Debt | 57.71M | 62.24M | 58.15M | 57.02M | 101.74M | 108.40M | 101.20M | 105.68M | 106.24M | 106.06M | 106.00M | 105.55M |
| Cash & Equiv | 38.09M | 34.33M | 49.66M | 21.36M | 62.89M | 66.66M | 34.55M | 35.62M | 96.49M | 22.46M | 21.12M | 102.27M |
| Book Value | 202.86M | 107.54M | 120.16M | 129.44M | 123.03M | 145.95M | 178.51M | 239.98M | 288.87M | 93.11M | 139.51M | 186.36M |
| Return on Equity | -0.01 | -0.14 | -0.11 | 0.03 | -0.21 | -0.23 | -0.36 | -0.22 | -0.17 | -0.53 | -0.36 | -0.24 |
LXRX News
Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
Lexicon Pharmaceuticals Q1 Earnings Call Highlights
Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2026 Earnings Call Transcript
Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1
Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates
Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital
Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Passes Above Two Hundred Day Moving Average – Here’s Why
LXRX Stock Up as NVO Initiates Phase I Study of Partnered Obesity Drug